BridgeBio Pharma LLC
CIK: 0002076615
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (100.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BBOT
BridgeBio Oncology Therapeutics, Inc.
10% Owner
Discretionary Trading P&L
Holdings
About BridgeBio Pharma LLC
BridgeBio Pharma LLC (SEC CIK 0002076615) files insider reports with the SEC as 10% Owner of BridgeBio Oncology Therapeutics, Inc. (BBOT).
Signal8 holds 2 ownership filings by BridgeBio Pharma LLC (1 Form 3, 1 Form 4), filed between Aug 18, 2025 and Oct 16, 2025. Those filings report 1 transaction, the latest on Oct 10, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on BridgeBio Pharma LLC's filings is in PALO ALTO, CA.
Recent filings by BridgeBio Pharma LLC
- Oct 10, 2025: Other transaction of BBOT shares (Form 4, code J).
Other insiders filing for BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Cobo Marc, Principal Accounting Officer
- Elmelech Idan, COO & Principal Financial Ofcr
- Beltran Pedro, President and CEO
- Ben Yong, Chief Med & Dev Officer
- Chen Bihua, Director
- Tipirneni Praveen P., Director